The firm served as lead counsel for a national research university, asserting a constructive trust theory to protect the university's rights in an antiviral nucleoside analogue active against HIV and HBV, under circumstances in which a pharmaceutical company had filed a U.K. patent application for the drug at issue, without naming inventors.  The client's constructive trust claims survived summary judgment and the case settled on confidential terms, under which the client secured the intellectual property of its inventors.

Experience Center

Match our Experience to Your Needs

Experience Highlights

Multiple acquisitions by New York Community Bancorp Inc.
Represented New York Community Bancorp Inc. in its $168.4 million acquisition of Synergy Financial Group Inc., its $260.0 million acquisition of more
Trademark enforcement services for Fortune 500 consumer electronics and computer software multinational corporation
Represents a California-based Fortune 500 multinational corporation that designs and manufactures consumer electronics and computer software more
Trust preferred securities offering for New York Community Bancorp Inc.
Represented New York Community Bancorp Inc. in connection with its redemption of $80.0 of trust preferred securities and subsequent issuance of more
Tax advice for a major U.S. pension plan
Advised a major U.S. pension plan on tax matters related to its alternative investments in hedge and private equity funds. more